Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

0:00
2:14
Reculer de 15 secondes
Avancer de 15 secondes
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

D'autres épisodes de "Pharmaceutical Executive"